The Fanger Center, an Innovative Collaboration with Celdara Medical and the New Hampshire Academy of Science, Opens at Crossroads Academy

On August 26, 2021 Celdara Medical, LLC (Celdara), The New Hampshire Academy of Science (NHAS), and Crossroads Academy reported the opening of the Fanger Center (Press release, Celdara Medical, AUG 26, 2021, View Source [SID1234586956]). The Fanger Center is an adaptable, cutting-edge facility that functions dually as the Crossroads Academy middle school by day and a New Hampshire Academy of Sciences STEM lab outside of school hours, enabling afterschool, holiday, and summer use. This unique collaboration makes the Fanger Center accessible to STEM-interested middle- and high-school students across the region through NHAS Programs, which include need-based financial aid. Constructed on the Crossroads Academy campus in Lyme, NH, the purpose-built facility was supported by Celdara and named after Dr. Michael Fanger, who co-founded Celdara Medical in 2008 with Dr. Jake Reder. The new facility, designed for chemistry, biology, mathematics, engineering, and computer science, is available to students across New Hampshire and Vermont. An outdoor ribbon cutting ceremony was held today for students and teachers to celebrate the start of the school year in the new space.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The NHAS has a mission to further the work of scientists and future scientists in New Hampshire by providing a forum for scientific discussion, interaction, and collaboration," notes NHAS Executive Director, Dr. Peter Faletra. "The Fanger Center provides an expanded space for students from all our communities to engage in authentic scientific research with teachers and STEM professionals through an apprenticeship model. NHAS intends to be a main hub for STEM opportunities in the states of NH and VT, with The Fanger Center serving as its flagship STEM research Center. Accessibility is core to our efforts; it is our goal to ensure that motivated students can attend, independent of their financial means."

Crossroads Head of School, Mr. Dan Morrissey, adds: "At Crossroads Academy, our faculty set children on learning journeys in every field of discovery, teaching them that knowledge and virtue – strong minds and kind hearts – can change the world. Like Dr. Fanger, our community is eager to create a better future and is continually exploring ways to do so. The inauguration of the Fanger Center on our 30th Anniversary represents our continued investment in thought leadership and innovation. We are thrilled that the region’s middle and high school students will have the opportunity to engage in high quality curricular and extra-curricular science and engineering research through our unique partnership with NHAS."

The Fanger Center is a replicable and scalable model for schools worldwide and builds upon the success of the current NHAS STEM lab. In addition to regional STEM outreach programs, teacher training and authentic research experiences for students, the existing NHAS STEM lab has resulted in over 100 students from 15 regional schools publishing their research with the American Junior Academy of Science and presenting their work at the annual meetings of the American Association for the Advancement for Science (AAAS). The Fanger Center expands the existing 1,200 square feet of biology lab space to include an additional 2,500 square feet of lab space, in addition to offices, conference spaces, and future-ready maker spaces, all focused on the physical sciences, computer science and engineering.

"Mike and I founded Celdara to transform the work of leading scientists into products and services that can help humanity. Mike gave immeasurably to the field of scientific education, as a mentor, entrepreneur, and academician. Increasing equitable access to educational opportunities and investing in STEM leaders of the future is a wonderful way to honor Mike’s legacy. Some of the next generation of leading scientists, mathematicians, and engineers will find their inspiration here," said Jake Reder, co-founder and CEO of Celdara Medical.

In 1981, Dr. Fanger joined Dartmouth Medical School’s Immunology Program, creating a world-renowned Department of Microbiology and Immunology, for which he served as Chairperson for a decade. As an entrepreneur, Dr. Fanger cofounded the pioneering biotechnology company Medarex, generating technology which created nearly half of the human antibodies approved to date. Two Medarex medicines ignited the immunoncology revolution, providing hope for previously incurable patients and saving thousands of lives. In 2018, Drs. Jim Allison and Tasuku Honjo received the Nobel Prize in Medicine for their pioneering work that led to these world changing Medarex drugs.

"Mike’s impact in the biotech industry is the stuff of legend, but for the many of us that he inspired, his teaching, counselling, advising, mentoring and friendship may be even more impactful. These virtues are a big part of why we are honoring his legacy with this Center. My hope is that every student who passes through these doors will learn something about Mike and realize that they too can be great by doing good," said Reder.

Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

On August 26, 2021 Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, reported that management will present at the Morgan Stanley 19th Annual Global Healthcare Conference (virtual), on Thursday, September 9, 2021 at 11:00 am ET (Press release, Compugen, AUG 26, 2021, View Source [SID1234586949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investor Relations section of Compugen’s website at www.cgen.com. A replay will be available following the live event.

MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021

On August 26, 2021 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that the Company will release its 2021 fiscal year end financial results after the close of the U.S. financial markets on September 2, 2021 (Press release, MEI Pharma, AUG 26, 2021, View Source [SID1234586948]). The Company will host a conference call and live webcast with the investment community to provide a corporate overview and update the same day at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast Information

When: September 2, 2021, 5:00 p.m. ET
Dial-in: 1-833-974-2378 (United States) or 1-412-317-5771 (International)
When requested, please ask the operator to join the MEI Pharma earnings call
Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of MEI’s website at: www.meipharma.com. A replay of the conference call will be archived for at least 30 days after the call.

Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference

On August 26, 2021 Johnson & Johnson (NYSE: JNJ) reported thayt it will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28th (Press release, Johnson & Johnson, AUG 26, 2021, View Source;johnson-to-participate-in-the-cantor-virtual-global-healthcare-conference-301363618.html [SID1234586947]). Mathai Mammen, Global Head, Research & Development Janssen Research Development and Scott White, Company Group Chairman NA Pharmaceuticals will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately 48-hrs after the live webcast.

Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer

On August 26, 2021 Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, reported that the first person has been dosed in China as part of the global Phase 3 registration trial, TROPiCS-04, in metastatic urothelial cancer (UC) (Press release, Everest Medicines, AUG 26, 2021, View Source [SID1234586946]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The multicenter, open-label randomized controlled trial will evaluate sacituzumab govitecan-hziy (SG) compared with standard of care chemotherapeutic options in people with metastatic or locally advanced unresectable UC who have progressed after prior therapy with a platinum-based regimen and anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy. The trial includes two study arms to evaluate SG compared to treatment of physician’s choice (TPC). The primary endpoint of the trial is overall survival.

"We are excited to continue advancing development of SG for people in China with metastatic UC – a devastating and fatal disease that continues to experience increasing incidence in the region," said Dr. Yang Shi, Chief Medical Officer for Oncology at Everest Medicines. "This comprehensive and ongoing global study has the potential to add to the existing and robust suite of data already generated for this novel therapeutic candidate."

About Urothelial Cancer

Urothelial cancer is the one of the most common malignancies diagnosed in China, with the five-year survival rate of metastatic UC estimated to be only 4.6%.[1] There is a significant need for new treatment options for people with UC who have failed platinum-based chemotherapies and checkpoint inhibitors. Urothelial cancer begins in urothelial cells that line the urethra, bladder, ureters, renal pelvis, and some other organs that make up the urinary system. It is estimated that there are more than 80,000 new cases of UC and nearly 33,000 deaths from UC in China per year.[2]

About Sacituzumab Govitecan-hziy

Sacituzumab govitecan-hziy is a first-in-class, antibody-drug conjugate (ADC) directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. SG received accelerated approval for advanced or metastatic UC following platinum-containing chemotherapy and a PD-1/PD-L1 inhibitor in the U.S. in April 2021.